<H1>Chapter DOI: 10.1208/aapsj070248<br/>Cited-By Count: 83</H1><table border="1" width="30%"><tr><td>Total References</td><td>88</td></tr><tr><td>Springer references</td><td>22</td></tr><tr><td>Non Springer references</td><td>66</td></tr><tr><td>BibStructured Count</td><td width="10%">84</td></tr><tr><td>BibUnstructured Count</td><td width="10%">4</td></tr><tr><td>DOI already available in SpringerLink</td><td>61</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>8</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>9</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>8</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1983;8:355&#8211;364.</td><td><a href=http://dx.doi.org/10.2165/00003088-198308040-00006>10.2165/00003088-198308040-00006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Grasela TH Jr, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data.<Emphasis Type="Italic">Dev Pharmacol Ther</Emphasis>. 1985;8:374&#8211;383.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Kelman AW, Thomson AH, Whiting B, et al. Estimation of gentamicin elearance and volume of distribution in neonates and young children.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1984;18:685&#8211;692.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.<Emphasis Type="Italic">JAMA</Emphasis>. 2003;290:905&#8211;911.</td><td><a href=http://dx.doi.org/10.1001/jama.290.7.905>10.1001/jama.290.7.905</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibBook</td><td>CDER/FDA. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products&#8212;Draft Guidance. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research, 1998.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2003;43:698&#8211;710.</td><td><a href=http://dx.doi.org/10.1177/0091270003254802>10.1177/0091270003254802</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Chatelut E, Boddy AV, Peng B, et al. Population pharmacokinetics of carboplatin in children.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1996;59:436&#8211;443.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(96)90113-7>10.1016/S0009-9236(96)90113-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:1845&#8211;1855.</td><td><a href=http://dx.doi.org/10.1023/A:1016215116835>10.1023/A:1016215116835</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Ette EI, Williams P, Fadiran E, Ajayi FO, Onyiah LC. The process of knowledge discovery from large pharmacokinetic data sets.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2001;41:25&#8211;34.</td><td><a href=http://dx.doi.org/10.1177/00912700122009809>10.1177/00912700122009809</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1999;16:709&#8211;717.</td><td><a href=http://dx.doi.org/10.1023/A:1018828709196>10.1023/A:1018828709196</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2002;54:131&#8211;139.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2002.01598.x>10.1046/j.1365-2125.2002.01598.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children.<Emphasis Type="Italic">Int J Clin Pharmacol Ther</Emphasis>. 2002;40:485&#8211;492.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.5414/CPP40485>10.5414/CPP40485</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese?.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2004;58:119&#8211;133.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.2004.02157.x>10.1111/j.1365-2125.2004.02157.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Mahmood I. Allometric issues in drug development.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1999;88:1101&#8211;1106.</td><td><a href=http://dx.doi.org/10.1021/js9902163>10.1021/js9902163</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Bonate PL, Howard D. Prospective allometric scaling: does the emperor have clothes?.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2000;40:335&#8211;340.</td><td><a href=http://dx.doi.org/10.1177/00912700022009017>10.1177/00912700022009017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Mahmood I. Interspecies scaling: predicting oral clearance in humans.<Emphasis Type="Italic">Am J Ther</Emphasis>. 2002;9:35&#8211;42.</td><td><a href=http://dx.doi.org/10.1097/00045391-200201000-00008>10.1097/00045391-200201000-00008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms.<Emphasis Type="Italic">Science</Emphasis>. 1999;284:1677&#8211;1679.</td><td><a href=http://dx.doi.org/10.1126/science.284.5420.1677>10.1126/science.284.5420.1677</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology.<Emphasis Type="Italic">Science</Emphasis>. 1997;276:122&#8211;126.</td><td><a href=http://dx.doi.org/10.1126/science.276.5309.122>10.1126/science.276.5309.122</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Weibel ER. Physiology: the pitfalls of power laws.<Emphasis Type="Italic">Nature</Emphasis>. 2002;417:131&#8211;132.</td><td><a href=http://dx.doi.org/10.1038/417131a>10.1038/417131a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Holford NH. A size standard for pharmacokinetics.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1996;30:329&#8211;332.</td><td><a href=http://dx.doi.org/10.2165/00003088-199630050-00001>10.2165/00003088-199630050-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2000;50:125&#8211;134.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2000.00231.x>10.1046/j.1365-2125.2000.00231.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Hu TM, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainty versus universality.<Emphasis Type="Italic">AAPS PharmSci</Emphasis>. 2001;3:E29.</td><td><a href=http://dx.doi.org/10.1208/ps030429>10.1208/ps030429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1982;10:201&#8211;227.</td><td><a href=http://dx.doi.org/10.1007/BF01062336>10.1007/BF01062336</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1997;33:313&#8211;327.</td><td><a href=http://dx.doi.org/10.2165/00003088-199733050-00001>10.2165/00003088-199733050-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kleiber</span> <span style='background:#DDDDDD'>M.</span></span></aug> <span style='background:#CCCCFF'>Body size and metabolism</span>. <span style='background:#CCFF99'><i>Hilgardia</i></span>. <span style='background:#66FF66'>1932</span>;<span style='background:#D279FF'>6315&#8211;6353</span>.</td><td><a href=http://dx.doi.org/10.3733/hilg.v06n11p315>10.3733/hilg.v06n11p315</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, JournalTitle, Year</td><td>CrossRef</td></tr><tr><td>CR26</td><td>BibArticle</td><td>McMahon T. Size and shape in biology.<Emphasis Type="Italic">Science</Emphasis>. 1973;179:1201&#8211;1204.</td><td><a href=http://dx.doi.org/10.1126/science.179.4079.1201>10.1126/science.179.4079.1201</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Anderson BJ, Holford NH, Woollard GA, chan PL. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1998;46:237&#8211;243.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.1998.00780.x>10.1046/j.1365-2125.1998.00780.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Agutter</span> <span style='background:#DDDDDD'>PS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wheatley</span> <span style='background:#DDDDDD'>DN</span></span></aug>. <span style='background:#CCCCFF'>Metabolic scaling: consensus or controversy?</span><span style='background:#CCFF99'><i>Theor Biol Med Model</i></span>. <span style='background:#66FF66'>2004</span>:<span style='background:#D279FF'>1&#8211;13</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Darveau CA, Suarez RK, Andrews RD, Hochachka PW. Allometric cascade as a unifying principle of body mass effects on metabolism.<Emphasis Type="Italic">Nature</Emphasis>. 2002;417:166&#8211;170.</td><td><a href=http://dx.doi.org/10.1038/417166a>10.1038/417166a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Rodman JH. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design.<Emphasis Type="Italic">J Adolesc Health</Emphasis>. 1994;15:654&#8211;662.</td><td><a href=http://dx.doi.org/10.1016/S1054-139X(94)90633-5>10.1016/S1054-139X(94)90633-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Bailey JM, Hoffman TM, Wessel DL, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2004;31:43&#8211;59.</td><td><a href=http://dx.doi.org/10.1023/B:JOPA.0000029488.45177.48>10.1023/B:JOPA.0000029488.45177.48</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Martin-Suarez A, Falcao AC, Outeda M, et al. Population pharmacokinetics of digoxin in pediatric patients.<Emphasis Type="Italic">Ther Drug Monit</Emphasis>. 2002;24:742&#8211;745.</td><td><a href=http://dx.doi.org/10.1097/00007691-200212000-00010>10.1097/00007691-200212000-00010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Schaefer HG, Stass H, Wedgwood J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.<Emphasis Type="Italic">Antimicrob Agents Chemother</Emphasis>. 1996;40:29&#8211;34.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Christensen ML, Mottern RK, Jabbour JT, Fuseau E. Pharmacokinetics of sumatriptan nasal spray in children.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2004;44:359&#8211;367.</td><td><a href=http://dx.doi.org/10.1177/0091270004263467>10.1177/0091270004263467</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dubois</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dubois</span> <span style='background:#DDDDDD'>E.</span></span></aug> A formula to estimate the approximate surface area if height and weight be known. <i>Arch Int Med</i>. <span style='background:#66FF66'>1916</span>;<span style='background:#D279FF'>17863&#8211;17871</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Gehan EA, George SL. Estimation of human body surface area from height and weight.<Emphasis Type="Italic">Cancer Chemother Rep</Emphasis>. 1970;54:225&#8211;235.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Mosteller RD. Simplified calculation of body-surface area.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1987;317:1098.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:555&#8211;575.</td><td><a href=http://dx.doi.org/10.1023/A:1014412521191>10.1023/A:1014412521191</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Sallas WM, Milosavljev S, D'Souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;74:138&#8211;149.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(03)00124-3>10.1016/S0009-9236(03)00124-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Reilly JJ, Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 1993;32:411&#8211;418.</td><td><a href=http://dx.doi.org/10.1007/BF00685883>10.1007/BF00685883</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Yukawa E, Satou M, Nonaka T, et al. Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2002;42:81&#8211;88.</td><td><a href=http://dx.doi.org/10.1177/0091270002042001009>10.1177/0091270002042001009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1992;20:511&#8211;528.</td><td><a href=http://dx.doi.org/10.1007/BF01061469>10.1007/BF01061469</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2003;43:133&#8211;140.</td><td><a href=http://dx.doi.org/10.1177/0091270002239821>10.1177/0091270002239821</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Panetta JC, Iacono LC, Adamson PC, Stewart CF. The importance of pharmacokinetic limited sampling models for childhood cancer drug development.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2003;9:5068&#8211;5077.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Desoize B, Marechal F, Cattan A. Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.<Emphasis Type="Italic">Br J Cancer</Emphasis>. 1990;62:840&#8211;841.</td><td><a href=http://dx.doi.org/10.1038/bjc.1990.390>10.1038/bjc.1990.390</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, FirstPage, VolumeID, JournalTitle, Year</td><td>CrossRef</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Kobayashi K, Ratain MJ. Pharmacodynamics and long-term toxicity of etoposide.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 1994;34(suppl):S64-S68.</td><td><a href=http://dx.doi.org/10.1007/BF00684866>10.1007/BF00684866</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Minami H, Ratain MJ, Ando Y, Shimokata K. Pharmacodynamic modeling of prolonged administration of etoposide.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 1996;39:61&#8211;66.</td><td><a href=http://dx.doi.org/10.1007/s002800050538>10.1007/s002800050538</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Relling MV, McLeod H, Bowman L, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1994;56:503&#8211;511.</td><td><a href=http://dx.doi.org/10.1038/clpt.1994.171>10.1038/clpt.1994.171</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1995;58:99&#8211;107.</td><td><a href=http://dx.doi.org/10.1016/0009-9236(95)90077-2>10.1016/0009-9236(95)90077-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Panetta JC, Wilkinson M, Pui CH, Relling MV. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2002;29:171&#8211;188.</td><td><a href=http://dx.doi.org/10.1023/A:1019755608555>10.1023/A:1019755608555</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Kirstein MN, Panetta JC, Gajjar A, et al. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 2005;55:433&#8211;438.</td><td><a href=http://dx.doi.org/10.1007/s00280-004-0896-9>10.1007/s00280-004-0896-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1981;9:739&#8211;756.</td><td><a href=http://dx.doi.org/10.1007/BF01070904>10.1007/BF01070904</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>D'Argenio DZ. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.<Emphasis Type="Italic">Math Biosci</Emphasis>. 1990;99:105&#8211;118.</td><td><a href=http://dx.doi.org/10.1016/0025-5564(90)90141-K>10.1016/0025-5564(90)90141-K</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibBook</td><td>D'Argenio DZ, Schumitzky A.<Emphasis Type="Italic">ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software</Emphasis>. Los Angeles: Biomedical Simulations Resource; 1997.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.<Emphasis Type="Italic">Drug Metab Rev</Emphasis>. 1984;15:265&#8211;292.</td><td><a href=http://dx.doi.org/10.3109/03602538409015066>10.3109/03602538409015066</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Retout S, Duffull S, Mentre F. Development and implementation of the population Fischer information matrix for the evaluation of population pharmacokinetic designs.<Emphasis Type="Italic">Comput Methods Programs Biomed</Emphasis>. 2001;65:141&#8211;151.</td><td><a href=http://dx.doi.org/10.1016/S0169-2607(00)00117-6>10.1016/S0169-2607(00)00117-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Sheiner LB, Beal SL. Some suggestions for measuring predictive performance.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1981;9:503&#8211;512.</td><td><a href=http://dx.doi.org/10.1007/BF01060893>10.1007/BF01060893</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.<Emphasis Type="Italic">J Clin Oncol</Emphasis>. 2004;22:3357&#8211;3365.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.10.103>10.1200/JCO.2004.10.103</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.<Emphasis Type="Italic">Clin Cancer Res</Emphasis>. 2003;9:633&#8211;640.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 1998;338:499&#8211;505.</td><td><a href=http://dx.doi.org/10.1056/NEJM199802193380803>10.1056/NEJM199802193380803</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Wilson JT. An update on the therapeutic orphan.<Emphasis Type="Italic">Pediatrics</Emphasis>. 1999;104:585&#8211;590.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Lockwood PA, Cook JA, Ewy WE, Mandema JW. The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2003;20:1752&#8211;1759.</td><td><a href=http://dx.doi.org/10.1023/B:PHAM.0000003371.32474.ee>10.1023/B:PHAM.0000003371.32474.ee</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.<Emphasis Type="Italic">Arthritis Rheum</Emphasis>. 2003;48:3031&#8211;3038.</td><td><a href=http://dx.doi.org/10.1002/art.11293>10.1002/art.11293</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.<Emphasis Type="Italic">Invest New Drugs</Emphasis>. 2003;21:195&#8211;223.</td><td><a href=http://dx.doi.org/10.1023/A:1023525513696>10.1023/A:1023525513696</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.<Emphasis Type="Italic">Int J Gynecol Cancer</Emphasis>. 2003;13:251&#8211;261.</td><td><a href=http://dx.doi.org/10.1046/j.1525-1438.2003.13202.x>10.1046/j.1525-1438.2003.13202.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis>. 2003;52:1S3&#8211;1S15.</td><td><a href=http://dx.doi.org/10.1007/s00280-003-0653-5>10.1007/s00280-003-0653-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Konski A, Sherman E, Krahn M, et al. Monte Carlo simulation of a Markov model for a phase III clinical trial evaluating the addition of total androgen suppression (TAS) to radiation versus radiation alone for locally advanced prostate cancer (RTOG 86-10).<Emphasis Type="Italic">Int J Radiat Oncol Biol Phys</Emphasis>. 2003;57:S215-S216.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0360-3016(03)01028-9>10.1016/S0360-3016(03)01028-9</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.<Emphasis Type="Italic">Oncology (Huntingt)</Emphasis>. 2002;16:37&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2000;68:677&#8211;687.</td><td><a href=http://dx.doi.org/10.1067/mcp.2000.111948>10.1067/mcp.2000.111948</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Nestorov I, Graham G, Duffull S, Aarons L, Fuseau E, Coates P. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2001;18:1210&#8211;1219.</td><td><a href=http://dx.doi.org/10.1023/A:1010943430471>10.1023/A:1010943430471</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Chabaud S, Girard P, Nony P, Boissel JP. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2002;29:339&#8211;363.</td><td><a href=http://dx.doi.org/10.1023/A:1020953107162>10.1023/A:1020953107162</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:209&#8211;234.</td><td><a href=http://dx.doi.org/10.1146/annurev.pharmtox.40.1.209>10.1146/annurev.pharmtox.40.1.209</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Ette EI, Sun H, Ludden TM. Balanced designs in longitudinal population pharmacokinetic studies.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1998;38:417&#8211;423.</td><td><a href=http://dx.doi.org/10.1002/j.1552-4604.1998.tb04446.x>10.1002/j.1552-4604.1998.tb04446.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Author_FamilyName_2, Author_FamilyName_1, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Ette EI, Sun H, Ludden TM. Ignorability and parameter estimation in longitudinal pharmacokinetic studies.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1998;38:221&#8211;226.</td><td><a href=http://dx.doi.org/10.1002/j.1552-4604.1998.tb04419.x>10.1002/j.1552-4604.1998.tb04419.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, ArticleTitle, FirstPage, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Fernandez de Gatta MM, Tamayo M, Garcia MJ, et al. Prediction of imipramine serum levels in enuretic children by a Bayesian method: comparison with two other conventional dosing methods.<Emphasis Type="Italic">Ther Drug Monit</Emphasis>. 1989;11:637&#8211;641.</td><td><a href=http://dx.doi.org/10.1097/00007691-198911000-00004>10.1097/00007691-198911000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Kraus DM, Dusik CM, Rodvold KA, Campbell MM, Kecskes SA. Bayesian forecasting of gentamicin pharmacokinetics in pediatric intensive care unit patients.<Emphasis Type="Italic">Pediatr Infect Dis J</Emphasis>. 1993;12:713&#8211;718.</td><td><a href=http://dx.doi.org/10.1097/00006454-199309000-00002>10.1097/00006454-199309000-00002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>el Desoky E, Ghazal MH, Mohamed MA, Klotz U. Disposition of intravenous theophylline in asthmatic children: Bayesian approach vs direct pharmacokinetic calculations.<Emphasis Type="Italic">Jpn J Pharmacol</Emphasis>. 1997;75:13&#8211;20.</td><td><a href=http://dx.doi.org/10.1254/jjp.75.13>10.1254/jjp.75.13</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Lares-Asseff I, Lugo-Goytia G, Perez-Guille MG, Flores-Perez J, Juarez-Olguin H, Raquel Moreno MA. Cefuroxime Bayesian pharmacokinetics in severely ill septic children.<Emphasis Type="Italic">Rev Invest Clin</Emphasis>. 1998;50:311&#8211;316.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Lares-Asseff I, Lugo-Goytia G, Perez-Guille MG, et al. Bayesian prediction of chloramphenicol blood levels in children with sepsis and malnutrition.<Emphasis Type="Italic">Rev Invest Clin</Emphasis>. 1999;51:159&#8211;165.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Wrishko RE, Levine M, Khoo D, Abbott P, Hamilton D. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.<Emphasis Type="Italic">Ther Drug Monit</Emphasis>. 2000;22:522&#8211;531.</td><td><a href=http://dx.doi.org/10.1097/00007691-200010000-00004>10.1097/00007691-200010000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Bressolle F, Gouby A, Martinez JM, et al. Population pharmacokinetics of amikacin in critically ill patients.<Emphasis Type="Italic">Antimicrob Agents Chemother</Emphasis>. 1996;40:1682&#8211;1689.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.<Emphasis Type="Italic">Int J Clin Pharmacol Ther</Emphasis>. 2001;39:431&#8211;446.</td><td><a href=http://dx.doi.org/10.5414/CPP39431>10.5414/CPP39431</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR83</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Andrew</span> <span style='background:#DDDDDD'>MV</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mitchell</span> <span style='background:#DDDDDD'>DJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Barrett</span> <span style='background:#DDDDDD'>JS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hainer</span> <span style='background:#DDDDDD'>JW.</span></span></aug>, <span style='background:#FFD9B3'>Design aspects of dose-finding trials in pediatric patients with severe TE: Tinzaparin pediatric study [abstract]</span>. <i>Thromb Heamostasis</i>. <span style='background:#66FF66'>2001</span>;<span style='background:#D279FF'>86</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84</td><td>BibChapter</td><td>Gastonguay MR, Gibiansky E, Gibiansky L, Barrett JS. Optimizing a Bayesian dose-adjustment scheme for a pediatric trial: a simulation study. In: Kimko HC, Duffull SB, eds.<Emphasis Type="Italic">Simulation for Designing Clinical Trials</Emphasis>. New York: Marcel Dekker; 2002;369&#8211;390.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1201/9780203910276>10.1201/9780203910276</a></td><td><b>CrossRef-Web</b></td>
<td>Year, BookTitle</td><td>CrossRef</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Willis C, Staatz CE, Tett SE. Bayesian forcasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients.<Emphasis Type="Italic">Ther Drug Monit</Emphasis>. 2003;25:158&#8211;166.</td><td><a href=http://dx.doi.org/10.1097/00007691-200304000-00004>10.1097/00007691-200304000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>de Wildt SN, de Hoog M, Vinks AA, van der Giesen E, van den Anker JN. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.<Emphasis Type="Italic">Crit Care Med</Emphasis>. 2003;31:1952&#8211;1958.</td><td><a href=http://dx.doi.org/10.1097/01.ccm.0000084806.15352.da>10.1097/01.ccm.0000084806.15352.da</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibBook</td><td>
                  <Emphasis Type="Italic">CDER/FDA</Emphasis>.<Emphasis Type="Italic">Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medicinal Products</Emphasis>. Rockville, MD: Food and Drug administration, Center for Drug Evaluation and Research, 2004.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children: normal values for age and sex.<Emphasis Type="Italic">J Pediatr</Emphasis>. 1976;88:828&#8211;830.</td><td><a href=http://dx.doi.org/10.1016/S0022-3476(76)81125-0>10.1016/S0022-3476(76)81125-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>